Welcome to our dedicated page for Genenta Science Spa news (Ticker: GNTA), a resource for investors and traders seeking the latest updates and insights on Genenta Science Spa stock.
Genenta Science S.p.A. (NASDAQ: GNTA) is a clinical-stage immuno-oncology company developing Temferon™, a hematopoietic stem cell therapy platform aimed at solid tumor cancers. The GNTA news feed on Stock Titan aggregates company-issued updates, regulatory disclosures, and other coverage that shed light on how this platform is progressing through clinical development and corporate milestones.
News about Genenta frequently centers on its Temferon clinical programs, including the TEM-GBM study in newly diagnosed glioblastoma multiforme (GBM) patients with an unmethylated MGMT gene promoter and Phase 1/2a work in metastatic renal cell carcinoma and other genitourinary tumors. Company releases discuss survival trends, long-term follow-up observations, and exploratory immune findings related to tumor microenvironment reprogramming and T cell responses.
Investors following GNTA can also expect coverage of financing transactions such as registered direct offerings of American Depositary Shares, mandatory convertible bond financings with institutional partners, and the use of at-the-market facilities, as well as updates on cash and short-term investments in the context of funding clinical trials. Additional news items highlight strategic collaborations with organizations like Anemocyte and AGC Biologics for plasmid DNA and cell therapy manufacturing, along with participation in biotech conferences and sector events.
Corporate governance and leadership developments, including board appointments, changes in executive roles, amendments to by-laws, and disclosures about insider share ownership, are also reported through Genenta’s press releases and Form 6-K filings. For readers tracking GNTA stock, this news page provides a centralized view of the company’s clinical, financial, and strategic updates. Bookmark the GNTA news section to review new releases and historical announcements as Genenta advances its immuno-oncology platform.
Genenta Science (NASDAQ: GNTA) has received approval from AIFA for a new Phase 1 clinical trial for metastatic Renal Cell Cancer (mRCC), expanding potential applications for its flagship product, Temferon™. This approval aligns with EMA standards. The company's ongoing TEM-GBM development program has completed a Phase 1 dose-ranging trial, confirming no dose-limiting toxicities across 24 patients. Temferon-derived cells remained detectable for over two years post-infusion, with treatment associated with a median survival of 16.8 months and a 25% increase in 2-year overall survival.
The new mRCC trial, targeting high-risk patients with a median overall survival of less than 2 years after multiple therapies, is expected to start in Q4 2024. Recent preclinical studies show synergy between Temferon and other immunotherapies in solid tumors. Genenta will present these developments at upcoming events, including Maxim Group's 2024 Healthcare Virtual Summit and the Society for Neuro-Oncology Annual Meeting.
Genenta Science (NASDAQ: GNTA) recently appointed five new directors to its Board of Directors, including John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider. The company aims to leverage the expertise of these new members to further develop its cell-based platform for treating solid tumors. The shareholders' meeting held on May 2, 2024, marked a significant step towards strengthening the company's leadership and strategic direction.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Genenta Science (NASDAQ: GNTA) announced its fiscal year 2022 financial results, revealing a net loss of €8.5 million, an increase from €5.5 million in 2021. The loss includes a net exchange rate gain of €2.3 million from USD to EUR conversion. The company reported no revenues for 2022, with R&D expenses rising to €5.3 million and G&A expenses at €5.7 million. Genenta holds a €6.4 million tax credit and €29.8 million in cash, estimated to sustain operations into Q1 2025. CEO Pierluigi Paracchi emphasized progress on their lead technology, Temferon, aimed at treating glioblastoma. The annual report is available on the company's investor relations site.
Genenta Science (NASDAQ: GNTA) has announced an amendment to its license agreement with Ospedale San Raffaele (OSR), now allowing access to all solid tumor indications, pending governmental consent. This expansion is expected to enhance Genenta's intellectual property position and treatment options for various cancers. CEO Pierluigi Paracchi highlighted promising preliminary data from the ongoing glioblastoma study, bolstering the decision for broader access. The amended agreement requires approval from the Italian government, which must respond within 90 days for the changes to take effect.
Genenta Science (NASDAQ: GNTA) announced that the FDA has granted Orphan Drug Designation to Temferon™ for glioblastoma multiforme (GBM) treatment. The designation aims to promote the development of Temferon™, a cell therapy targeting tumor microenvironments with immunomodulatory molecules. This decision is expected to enhance Genenta's clinical program addressing the significant unmet medical need in GBM, where about 60% have unmethylated MGMT promoter status. The ODD provides benefits such as federal grants, tax credits for trials, and a seven-year marketing exclusivity post-approval.